jz体育

<meter id="k8nvv"><object id="k8nvv"></object></meter>

      <mark id="k8nvv"><ol id="k8nvv"><source id="k8nvv"></source></ol></mark>
      1. <mark id="k8nvv"><ol id="k8nvv"></ol></mark>
        <code id="k8nvv"></code>
      2. <small id="k8nvv"></small>

      3. <small id="k8nvv"></small>
      4. <meter id="k8nvv"></meter>
          <mark id="k8nvv"><ruby id="k8nvv"></ruby></mark>
        1. <mark id="k8nvv"></mark>
          • President Li Xiaokun Elected Academician of the Chinese Academy of Engineering
          • On Nov.22th, the Chinese Academy of Engineering announced the list of newly-elected academicians. Li Xiaokun, president of Wenzhou Medical University, was elected as an academician of the Chinese Academy of Engineering.

            Li Xiaokun was recognized by the Ministry of Education (MoE) as Chang Jiang Scholars and National Outstanding Teacher. He is in charge of the Biological Drugs Innovation Team of MoE and leads a project under the program "Protein Machine and Life Regulation" of the National Key R&D Program of China.



            In the past 30 years, Li has been concentrating on the basic theory research and new drug development on macromolecule protein drugs represented by growth factors. Li focuses on growth factors which are closely related to the development and growth of the body, especially on the system theory research on the fibroblast growth factors (FGFs) family. He internationally pioneered a variety of new drugs (rb-bFGF,rh-bFGF,aFGF) promoting tissue repair and regeneration and drug-loaded medical equipment (FGF+Collagen), etc., which are widely applied to the treatment of burns, refractory ulcer, complications of diabetes and geriatric diseases, major disaster trauma and national defense war wounds. Based on above clinical translational research, Li first discovered and clarified the mechanism of FGFs family and metabolic diseases in the world, and put forward the theoretical hypothesis of "the FGF metabolic axis", providing new idea for the diagnosis and treatment of metabolic diseases, and opening up a new area for the research and development of FGF new drugs for metabolic diseases. He has published lots of papers in leading journals including Nature, Cell Meetab, Mol Cell and Circulation. Li acquired the Second Prize of 2009 State Technology Innovation Award, the Second Prize of 2018 National Science and Technology Progress Award, the Science and Technology Award of the Ho Leung Ho Lee Foundation, Tan Jia Zhen Life Sciences Award, Guanghua Engineering Science and Technology Award, and the Outstanding Contribution Award for Translational Medicine etc. He provides tools and methods for clinical research on regenerative medicine as well as important experience in the research and development of macromolecule protein drugs in China, and sets a model for the development of the recombination genetic drugs.



          <meter id="k8nvv"><object id="k8nvv"></object></meter>

              <mark id="k8nvv"><ol id="k8nvv"><source id="k8nvv"></source></ol></mark>
              1. <mark id="k8nvv"><ol id="k8nvv"></ol></mark>
                <code id="k8nvv"></code>
              2. <small id="k8nvv"></small>

              3. <small id="k8nvv"></small>
              4. <meter id="k8nvv"></meter>
                  <mark id="k8nvv"><ruby id="k8nvv"></ruby></mark>
                1. <mark id="k8nvv"></mark>
                2. win足球即时比分

                  足彩外围网站

                  中国体育竞彩网页

                  金鼎的彩的网址

                  索莱尔注册开户送

                  a8体育app

                  六福彩票注册平台

                  宏8彩票登录

                  at|登录